Cardiorobotics, Inc., a medical device company developing snake robot technologies for use in a wide range of surgical and interventional applications has closed on an $11.6 Million
private equity Series A round of financing. The round was led by Eagle Ventures and its co-investors, The Pittsburgh Life Sciences Greenhouse and The Slater Technology Fund and affiliated investors.
Funds raised in this round will support the advancement of the clinical product, a clinical feasibility trial on humans, and completion of
commercial product for regulatory approval in the United States and the European Union.
“This investment will be used to advance our core product, the cardioARMT, toward commercialization,” said Dr. Samuel Straface, Cardiorobotics, Inc.,
president and Chief Executive Officer. ”We’re pleased to have Eagle Ventures, The Pittsburgh Life Sciences Greenhouse, and The Slater Technology Fund and affiliated investors share our vision in providing single-port, off-pump treatments for patients with heart arrhythmias.”
“I am impressed by the combination of the breakthrough technology platform, experienced entrepreneurial leadership, and high commercialization potential
of the cardioARMT,” said Mel Pirchesky, president and Chief Executive Officer of Eagle Ventures.
Cardiorobotics’ is the global leader in snake robotics for minimally-invasive cardiac interventions, allowing minimally invasive
treatments for patients suffering with heart arrhythmias.
It’s Monday and Techburgher is still recovering from Whuff-aoke on Saturday night. The voice is back and we’re starting off the week with some exciting news from Cardiorobotics, a medical device company developing snake robot technologies for use in a wide range of surgical and interventional applications.
Cardiorobotics has closed on an $11.6 Million private equity Series A round of financing. The round was led by Eagle Ventures and its co-investors, The Pittsburgh Life Sciences Greenhouse and The Slater Technology Fund and affiliated investors.
Funds raised in this round will support the advancement of the clinical product, a clinical feasibility trial on humans, and completion of commercial product for regulatory approval in the United States and the European Union.
The investment will be used to advance the cardioARMT toward commercialization, said Dr. Samuel Straface, Cardiorobotics, Inc., president and Chief Executive Officer.
“I am impressed by the combination of the breakthrough technology platform, experienced entrepreneurial leadership, and high commercialization potential of the cardioARMT,” said Mel Pirchesky, president and Chief Executive Officer of Eagle Ventures.
Cardiorobotics’ is al leader in snake robotics for minimally-invasive cardiac interventions, allowing minimally invasive treatments for patients suffering with heart arrhythmias.
0 Responses to “Cardiorobotics Closes on $11.6M Funding Round”